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2012.10.0Abstract Reports about patients with acute promyelocytic leukemia from the Middle East are few;
in this study we are reporting our single center experience of treating 29 patients over 6 years. Acute
promyelocytic leukemia treatment response is markedly improved after the introduction of ATRA.
Treatment related complication is still an important issue particularly Differentiation Syndrome.
Prediction to its occurrence has been tried by other groups. We aimed to study all the possible pre-
dictive factors of acute promyelocytic leukemia. Our chemotherapy induction protocol is AIDA
protocol which includes ATRA 45 mg/m2/d in divided doses every12 h, and Idarubicin 12 mg/
m2/d IV on days 3, 5, 7, and 9. Differentiation Syndrome occurred in 48.3% of patients and was
mainly presented by pulmonary symptoms in 55.2%, 6 cases died during induction. None of the
predictive factors studied showed a statistically signiﬁcant difference between patients who devel-
oped Differentiation Syndrome and those who did not. Differentiation Syndrome did not affect
overall survival. Cox regression showed an inverse yet a non signiﬁcant association between PET-
HEMA and overall survival probability (P= 0.168). In conclusion, Differentiation Syndrome has
no clear predictive factor to date. The best approach is to hold ATRA and give dexamethasone
which is quite effective as reported in the literature. PETHEMA risk model has a moderately sig-
niﬁcant prognostic value.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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04Introduction
Acute Promyelocytic Leukemia (APL) is a type of acute mye-
loid leukemia characterized by the morphology of M3 in the
French–American–British classiﬁcation and by the presence
of translocation t (15; 17) [1,2]. All transretinoic acid is the
main stay in treatment [3]. There are a few reports about this
disease from our region compared to the western world. Our
retrospective study focused on disease characteristics, response
to treatment and utility of recent risk model. We aimed also toand hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
14 O. Elemam, D. Abdelmoetylook for all possible predictive factors of Differentiation Syn-
drome (DS) which were ﬁrst described in 1992 by Frankel
et al. [4] and represented the major complication through this
disease course: studies had reported conﬂicting results about
this [5,6]. In addition we will compare our data to other areas
of the world.Patients and methods
Twenty-nine patients with APL conﬁrmed by molecular study
were treated from August 2005 to June 2011 at King Fahad
Medical City, Riyadh, Saudi Arabia. Laboratory studies at
diagnosis included: hemogram of liver and renal function tests,
bone marrow studies (cytogenetics, ﬂowcytometry, FISH, and
PML-RARa by RT-PCR analysis). CBC and coagulation
parameter were monitored daily and coagulopathy was trea-
ted. All patients with ﬁbrinogen levels <100 mg/dl –with or
without active bleeding– received cryoprecipitate to maintain
the ﬁbrinogen above this level without the routine use of pro-
phylactic heparin. Platelets were transfused to maintain the
platelet count about 30,000/lL in patients not actively bleed-
ing and above 50,000/lL in patients actively bleeding. Fresh
frozen plasma was administered to patients actively bleeding
with prolonged PT and PTT, but not to patients without active
bleeding. Management of fever and neutropenia was according
to our leukemia unit guidelines. Packed red cell transfusion
was given if hemoglobin was less than 8 gm/dl.
The treatment regimen consisted of [7]:
I. Induction:
 All Trans-Retinoic Acid (ATRA) 45 mg/m2/d (to CR or
maximum of 56 days) administered in divided doses
12 h apart, after meals or with milk, rounded off to
the nearest 10 mg. Young patients (<16 years) received
reduced dose ATRA at 25 mg/m2/d.
 Idarubicin 12 mg/m2/d IV on days 3, 5, 7, and 9.
Patients older than 60 years received 3 doses only (5,
7, and 9).Patients with initial WBC> 10,000 started
Idarubicin on day 1.
 Prednisone 0.5 mg/kg/d PO for all patients D1–15 (IV
Methylprednisone was used for patients unable to take
PO).
 Bone marrow studies including morphology, cytogenet-
ics, FISH and molecular study to be performed on day
28 (and 56 if not in CR at day 28).
II. Consolidation therapy:
 First dose consolidation given within 2 weeks and no
later than 4 weeks after conﬁrmation of complete
remission.
 Idarubicin 12 mg/m2 IV repeated q 4 weeks (no later
than 6 weeks) · 6. ATRA 45 mg/m2 given as induction
daily for 2 weeks (started 24 h after Idarubicin dose)
for a total of 6 cycles.
 Peripheral blood for PCR obtained with each monthly
cycle.
 Bone marrow biopsy and aspirate studies including
morphology, cytogenetics, and molecular studies to be
done before the fourth Idarubicin consolidation, one
month after the completion of the consolidation.
III. Maintenance therapy started 4 weeks after completion
of the consolidation therapy. 6-Mercaptopurine 75 mg/m2 PO QD.
 Methotrexate 15 mg/m2 PO once a week.
 ATRA 45 mg/m2/d 14 days every 3 months.
 Doses of 6-Mercaptopurine and Methotrexate
decreased by 50% if ANC< 1500 and discontinued if
ANC< 1000.
 Maintenance given for 24 months.
Differentiation Syndrome was diagnosed based on the fol-
lowing clinical features: respiratory distress, pulmonary inﬁl-
trate, fever, weight gain, pleural effusion, renal impairment,
pericardial effusion, and hypotension. Once we diagnosed it,
we discontinued ATRA and dexamethasone (10 mg IV bid)
was given for a minimum of 3 days with or without Lasix
for reducing body weight. ATRA treatment was resumed once
symptoms of Differentiation Syndrome resolved. All other
complications at presentation and during treatment course
were recorded.
Patients were classiﬁed according to the risk of relapse
(PETHEMA) on the basis of WBC and platelet counts
(PLT) at diagnosis: Low risk WBC< 10 · 109/L and
PLT> 40 · 109/L; Intermediate risk WBC< 10 · 109/L and
PLT< 40 · 109/L, and High risk WBC> 10 · 109/L [8].
We calculated the body mass index (BMI) with the follow-
ing categories: Underweight =<18.5, Normal weight =
18.5–24.9, Overweight = 25–29.9 and Obesity = BMI of 30
or greater.
Complete Remission (CR) required patients to have
ANC> 1.5 · 109/L, platelet count of more than 100 · 109/L
and normo to hypocellular bone marrow with <5% blasts
plus promyelocytes. Survival time was calculated from the time
of diagnosis to the last follow-up. Resistant disease is deﬁned
as: the persistence of greater than 5% leukemic promyelocytes
56 days after the start of ATRA treatment.
Statistical methods
Data of quantitative variables (counts and measures) were pre-
sented as the median and the range because most of the vari-
ables were not found to be normally distributed; data of
categorical variables were presented as percentages. Compari-
sons between patients with and without Differentiation Syn-
drome were performed using the non-parametric Mann
Whitney U test for quantitative variables and the chi squared
test for categorical variables. When the expected observation
was too few as to violate the chi square test assumptions the
Fisher Exact test was used. Survival data were presented using
the Kaplan Meier method and comparisons were done by the
log rank test. Cox regression was used to examine the relation
between the overall survival and the PETHEMA risk category.
For all hypothesis tests used, the a priori alpha two tailed level
was set at 0.05 for statistical signiﬁcance. All analyses were
done using SPSS statistical package, Version 16.
Results
Patient characteristics are summarized in (Table 1). A total of
29 patients were treated from August 2005 to June 2011. The
age of patients ranged from 16 to 81 years, 75.9% were Saudi,
and 48.3% were females. At diagnosis, one patient had extra-
medullary skin disease and the main presenting symptom was
Table 1 Patient characteristics at diagnosis.
Patient characteristics No %
Gender
Male 15 51.5%
Female 14 48.3%
Median age 32
Age range 16–81 years
Nationality
Saudi 22 75.9%
Non Saudi 7
Extramedullary disease 1 3.4%
Main presenting symptoms
Fever 21 72.4%
Bleeding 25 86.2%
Bleeding site
Mucosal and skin 28 96.6%
Intracranial hemorrhage 1 3.4%
Median WBC 5
Range 0.4–115
Median HGB 8
Range 6–15
Median platelets 20
Range 9–70
DIC 2 6.9%
High LDH 20 69.0%
Hypogranular variant 5 17.2%
Hypercellular marrow 19 65.5%
Flowcytometry positive for
CD11b 2 6.9%
CD11c 1 3.4%
CD14 1 3.4%
CD33 24 82.8%
HLADR 1 3.4%
CD34 3 10.3%
CD45 25 86.2%
Negative forCD56 24 82.8%
Diﬀerentiation Syndrome
YES 14 48.3%
NO 15 51.7%
ATRA symptoms
Fever 12 41.4%
Weight gain 5 17.2%
Pulmonary symptoms 16 55.2%
Increase creatinine 1 3.4%
Complete remission 23 79.3%
Relapse 4 13.8%
Picc line related thrombosis 5 17.2%
Pethema risk model
Low risk 6 20.6%
Intermediate risk 8 27.5%
High risk 15 51.7%
BMI(obese category) 13 44.8%
Status of last follow up
Alive free of disease 21 72.4%
Alive with disease 0
Died 8 27.5%
Median follow up 17.13 months
Acute promyelocytic leukemia, study of predictive factors for Differentiation Syndrome 15bleeding (mucosal and skin), another patient had intracranial
hemorrhage, and two patients had DIC. The median WBC
at presentation was 1.5 · 109/L. The hypogranular variant
was found in 5 cases. Additional cytogenetic abnormalities
were found in 3 patients and included t (8; 15) and t (5; 7).
One patient who had t (5; 17) and was negative for t (15; 17)
died with septic shock during induction.Differentiation Syndrome occurred in 48.3% of patients
and mainly presented with pulmonary symptoms (55.2%) fol-
lowed by fever (41.4%) and weight gain (17.2%). Apart from
febrile neutropenia, other recorded complications were pseudo
obstruction of the large bowel, intracranial hemorrhage, sub-
hyoid and intraretinal bleeding. One patient developed pseu-
dotumor cerebri that manifested with persistent headache,
papilledema, diplopia with negative CSF and MRI brain.
The patient was treated with acetazolamide plus ATRA dis-
continuation and shifting to ATO. ATRA was resumed during
consolidation with no adverse events. One patient developed
visual and auditory hallucinations related to voriconazole.
Peripherally inserted central line (picc) related thrombosis oc-
curred in 5 patients (17.2%).
Six cases died during induction. Causes of early death were
massive hemoptysis, intracranial hemorrhage, acute myocar-
dial infarction, septic shock and alveolar hemorrhage (2 cases).
Complete remission was achieved in 79.3% of patients, 4 pa-
tients relapsed and 2 patients achieved remission with second
line treatment.
We studied all the possible predictive factors for Differenti-
ation Syndrome (see Table 2); none showed a statistically sig-
niﬁcant difference between patients who developed
Differentiation Syndrome and those who did not except one,
the percentage of females in patients with Differentiation Syn-
drome is signiﬁcantly greater than that of males (P value
0.027). Differentiation Syndrome did not affect the overall sur-
vival. (Fig. 2) shows a Kaplan Meier curve of the overall sur-
vival in relation to development of Differentiation Syndrome
(P value 0.390).
At diagnosis, 6 patients were in the low PETHEMA risk
group, 8 in the intermediate risk group, and 15 in the high risk
group. For the effect of PETHEMA risk category on the
cumulative overall survival, Cox regression showed a hazard
ratio of 2.19 (i.e. almost twice the hazard for each unit increase
in PETHEMA score). But this did not reach statistical signif-
icance (P= 0.168) (Fig. 1). Thirteen patients are in the obese
category (44.8%) and there was no difference in median BMI
between males and females. Out of 29 patients in this study, 23
are still alive and free of disease with a median follow up time
of 17.13 months.Discussion
In this retrospective study, we evaluated 29 patients of APL
treated over 5 years in our tertiary care center. The baseline
characteristics were similar to other reports. But based on
the risk score, 51.7% of our patients were in the high risk cat-
egory which is double the percentage reported by Pethema and
Gimema groups [8]. The complete remission rate was 79.3%.
This is slightly lower compared to that mentioned in other re-
ports since we have more high risk patients in our group for
being a tertiary care center accepts patients from all over the
country and so a delay in transferring patient may be expected.
All patients who survived the induction achieved complete
remission. Six patients died during induction (20.6%). The
main cause of induction death was hemorrhage. This was sim-
ilarly reported in a study which explored the causes and predic-
tive factors of induction death in patients with acute
promyelocytic leukemia [9]. All our patients were treated with
the AIDA protocol; except for a female patient who received
Table 2 Characteristics of patients with and without Differentiation Syndrome.
RAS(yes) RAS (no) P value
Gender
Male 4 (13.8%) 11(37.9%) 0.027
Female 10 (34.5%) 4(13.8%)
Age (median + range) 35 (24–61) 28 (13–53) 0.137
Fever at presentation 13 (44.8%) 8 (27.6%) 0.035
Bleeding 11 (37.9%) 14 (48.3%) 0.583
Median WBC (range) 2.08 (1–115) 9.30 (1–101) 0.462
Median HGB (range) 10 (6–14) 8.0 (6–15) 0.229
Median Platelets (range) 25(4–70) 19.80(5–69) 0.912
Median promyelocytes (range) 66.50 (1–90) 60.00 (1–94) 0.765
Median PT(range) 13.55 (11.30–18.30) 15.10 (10.00–17.90) 0.350
Median PTT(range) 28.60 (25–41) 29.35 (24–97) 0.258
Median Fibrinogen (range) 2.5 (0.9–4.7) 1.7 (1.1–2.7) 0.125
Median D-Dim (range) 2.0 (1.0–2.0) 2.0 (1.0–2.0) 0.897
Median LDH (range) 423 (203–1073) 339.5 (183–768) 0.285
Hypo granular 4(13.8%) 1(3.4%) 0.282
CD 11b
Positive 1(3.4%) 1(3.4%) 1.000
Negative 7(24.1%) 7(24.1%)
CD 11c
Positive 1(3.4%) 0 0.308
Negative 3(10.3%) 7(24.1%)
CD 13
Positive 10(34.5%) 11(37.9%) 0.827
Negative 3(10.3%) 2(6.8%)
CD 14
Positive 0 1(3.4%) 1.000
Negative 12(41.4%) 11(37.9%)
CD 33
Positive 0 1(3.4%) 0.368
Negative 12(41.4%) 12(41.4%)
CD 34
Positive 1(3.4%) 2(6.8%) 0.5
Negative 12(41.4%) 11(37.9%)
CD 45
Positive 13(44.8%) 12(41.4%) 0.308
Negative 0 1(3.4%)
Median weight (range) 68.65 (54–95) 74.0 (39.2–157.00) 0.255
Median height (range) 158.0 (146.9–190.00) 163.9 (150–170.3) 0.319
Median BMI ALL (range) 30.2 (20.8–263.6) 31.2 (14.59–63.69) 0.422
Median BMI male (range)
Median BMI female (range)
24.8(14.5–63.6)
32.5(20.8.5–263.6)
0.52
16 O. Elemam, D. AbdelmoetyATO (Arsenic trioxide) with a temporary stoppage of ATRA
due to pseudotumor cerebri. ATO was well tolerated and after
improvement treatment with ATRA was continued. Although
our induction protocol contained oral prednisone Differentia-
tion Syndrome, occurred in 48% of our patients and this is
higher than the incidence reported in other studies which ran-
ged from 6% to 36% [10–14]. This may be due to multiple fac-
tors as the type of induction chemotherapy, differences in
diagnostic criteria, delay in starting treatment in most cases,
and a great proportion of high risk patients in our cohort.
The high Differentiation Syndrome incidence may also be
due to its better recognition especially that the diagnosis of this
syndrome is only made by clinical criteria with multiple differ-
ential diagnoses. The pathogenesis of this syndrome is still
poorly understood; its clinical manifestations are suggesting
a role for cytokines, including interleukin-1b (IL-1b), IL-6,
IL-8, and tumor necrosis factor (TNF) a. APL cells undergo-
ing differentiation with ATRA have been demonstrated. Or-
gan inﬁltration by APL cells found in postmortem studies inDifferentiation Syndrome suggests that ATRA induces APL
cells to acquiesce leukemic cell–endothelial cell adhesion fol-
lowed by extravascular extravasation. In vitro, ATRA also
leads to aggregation of APL cells, which appears to be medi-
ated by induction by ATRA of the expression of high-afﬁnity
b2 integrins especially leukocyte function-associated antigen-1
[LFA-1] and their counter structure on the cell surface (in par-
ticular intercellular adhesion molecule [ICAM]-2). Methyl
prednisolone rapidly inhibits APL cell aggregation in a dose-
dependent manner, consistent with its prompt clinical effec-
tiveness in vivo [15]. Most of our patients were successfully
treated with dexamethazone which is reported to be effective
in other studies [6,16,17]. Two of our patients died with alveo-
lar hemorrhage which has been reported to be a manifestation
of Differentiation Syndrome [16]. So the best way is to try to
predict its occurrence. Regarding the predictive factors of Dif-
ferentiation Syndrome, there are conﬂicting results, some
pointed to the high leucocytic count at presentation [13,18].
Others found no correlation between leucocytic count and Dif-
Figure 2 Kaplan Meier curve of overall survival of all studied patients adjusted for PETHEMA risk category (beta coefﬁcient = 0.784,
beta exponent = 2.19, 95% CI (0.72–6.67).
Figure 1 Kaplan Meier curve of overall survival in relation to development of Differentiation Syndrome, P value 0.390.
Acute promyelocytic leukemia, study of predictive factors for Differentiation Syndrome 17ferentiation Syndrome incidence [5]. One study suggested that
patients with WBC more than 5000 on day 1, 6000 on day 5,
10000 on day 10 or 15000 on day 15 are at a high risk of
development of Differentiation Syndrome [19]. Our studyfound no association between WBC count at presentation
and Differentiation Syndrome development and this is similar
to the study of 413 cases of newly diagnosed acute promyelo-
cytic leukemia reported by the European APL group [15].
18 O. Elemam, D. AbdelmoetySteroid prophylaxis has been tested by other researchers,
where steroid was given to the patients whose WBC rose more
than 10,000 while on ATRA; none developed pulmonary tox-
icity but the number of patients studied was small and no ran-
domized trials were carried out to conﬁrm this [13,20,12,21].
Another study found that systemic steroids at the initiation
of ATRA and for 15 days lead to a lower incidence of severe
DS compared to IV dexamethazone given when the count
was more than 5 · 10 · 109/L before and during treatment
[22]. Our protocol did include prednisone from day 1 to 15
and the syndrome’s incidence approach 50%.
We found no association between Differentiation Syn-
drome occurrence and the expression of CD11b, CD11c,
CD13, CD14, CD33, CD34, or CD45. Other authors found
that the basal expression of CD13 (aminopeptidase N) –a cell
surface enzyme previously linked to tumor cell invasion and an
inferior outcome in patients with acute myeloid leukemia– to
be signiﬁcantly associated with both the development of the
syndrome and an elevated leukocyte count [6]. In the mean-
time, investigators returned to clinical examination and its va-
lue in predicting the occurrence of this syndrome. The
percentage of females in patients with Differentiation Syn-
drome is signiﬁcantly greater than that of males and this could
not be explained by BMI which showed no statistical differ-
ence between males and females. Multiple studies suggested
that BMI is a predictive factor for Differentiation Syndrome
which may be explained by the over-expression of Leptin
receptors on APL cells that can enhance their release of cyto-
kines after ATRA exposure leading to its complication [23,24].
BMI was the most powerful predictor in the multivariate anal-
ysis of Differentiation Syndrome as well as the disease relapse
in 144 patients treated with the AIDA protocol [25]. In this
study, we could not conﬁrm this, may be because most of
our patients were obese. In conclusion, Differentiation Syn-
drome has no clear predictive factors to date. The best ap-
proach is to hold ATRA and give dexamethasone which is
quite effective as reported in the literature. We report a higher
incidence of Differentiation Syndrome coupled with a great
proportion of high risk patients attending our institution.Conﬂict of interest
All authors declare no competing ﬁnancial interest.References
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